** Shares of U.S. drugmaker Eli Lilly LLY.N rise 2% to $859.99 premarket
** Co forecasts 2025 EPS between $22.50 and $24.00, above Street estimates of $22.86 at midpoint, according to data compiled by LSEG
** Co posts Q4 adj EPS of $5.32 vs estimates of $4.95, according to data compiled by LSEG
** Q4 sales of weight-loss drug Zepbound came in at $1.91 billion vs estimates of $2.03 billion -LLY
** Up to last close, stock gained 19.5% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。